
Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Metabolic peptide
GLP-2 (TR)
In stock
A dual-receptor research peptide used in controlled GIP and GLP-1 signalling studies.
Order within — · ships today Cutoff 10:00 · local time
Arrives Sep 21 - Sep 23 to Europe
GLP-2 (TR)
Price range: 39,90 € through 73,00 €
Dual incretin analogue for GLP-1 and GIP receptor pathway studies.
Scroll horizontally to reach every product-information tab.
Research overview
GLP-2 (TR)
GLP-2 (TR), described in scientific literature as tirzepatide or LY3298176, is a synthetic 39-amino-acid peptide investigated as a dual agonist at GIP and GLP-1 receptors. Its engineered sequence includes a C20 fatty-diacid group linked at Lys-20, a feature studied for reversible albumin association and an extended molecular profile.
Published work examines how the two incretin-receptor pathways interact, along with the compound's sequence design, receptor selectivity, binding behaviour, and downstream metabolic signalling in controlled research. Batch-specific identity and measured content remain governed by the signed analytical record for each strength.
Compound information
Specifications
Molecular profile
- Sequence
- Y-Aib-EGTFTSDYSI-Aib-LDKIAQ-K(AEEA-AEEA-gamma-Glu-C20 diacid)-AFVQWLIAGGPSSGAPPPS-NH2
- Molecular mass
- 4813.45 g/mol
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Dual GIPR/GLP-1R pathway research compound; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Latest test results
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg
> 99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 8.98 mg
- PurityPeptide screening
- > 99.8%
- Identity (FTIR)FTIR spectrum
- 997
- Identity (RT)Retention time
- 0.999
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- < 0.001 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 15mg
99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 13.41 mg
- PurityPeptide screening
- 99.8%
- Identity (FTIR)FTIR spectrum
- 995
- Identity (RT)Retention time
- 0.997
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.056 EU/mg
- Molecular Ion MassMS deconvolution
- 4813 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 30mg
99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 31.5 mg
- PurityPeptide screening
- 99.8%
- Identity (FTIR)FTIR spectrum
- 996
- Identity (RT)Retention time
- 0.998
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.007 EU/mg
- Molecular Ion MassMS deconvolution
- 4813 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
Coskun T, Sloop KW, Loghin C, et al. · 2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Discovery and receptor pharmacology of LY3298176.
Molecular Metabolism · 10.1016/j.molmet.2018.09.009 View source ↗National Center for Biotechnology Information
PubChem Compound Summary: Tirzepatide
Authoritative identity record for tirzepatide.
PubChem · View source ↗Frías JP, Davies MJ, Rosenstock J, et al. · 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Primary clinical research report for the compound described as tirzepatide.
The New England Journal of Medicine · 10.1056/nejmoa2107519 View source ↗National Center for Biotechnology Information



